Academic Journal
Impact of nonalcoholic fatty liver disease status change on antiviral efficacy of nucleos(t)ide analogues in HBeAg‐positive chronic hepatitis B
| العنوان: | Impact of nonalcoholic fatty liver disease status change on antiviral efficacy of nucleos(t)ide analogues in HBeAg‐positive chronic hepatitis B |
|---|---|
| المؤلفون: | Tang, Yanhua, Fan, Rong, Lan, Zhixian, Xie, Qing, Zhang, Jiping, Liang, Xieer, Wang, Hao, Tan, Deming, Cheng, Jun, Chen, Shijun, Ning, Qin, Bai, Xuefan, Xu, Min, Chen, Xinyue, Niu, Junqi, Shi, Junping, Ren, Hong, Gao, Zhiliang, Wang, Maorong, Dou, Xiaoguang, Hou, Jinlin, Sun, Jian |
| المساهمون: | National Natural Science Foundation of China |
| المصدر: | Journal of Medical Virology ; volume 95, issue 2 ; ISSN 0146-6615 1096-9071 |
| بيانات النشر: | Wiley |
| سنة النشر: | 2023 |
| المجموعة: | Wiley Online Library (Open Access Articles via Crossref) |
| الوصف: | Data on the dynamic changes in chronic hepatitis B (CHB) patients with nonalcoholic fatty liver disease (NAFLD) during antiviral therapy are scarce. We aimed to investigate the evolution of NAFLD status change in CHB patients treated with nucleos(t)ide analogues (NAs) and its influence on therapeutic outcomes. This retrospective study included 164 HBeAg‐positive CHB patients from a randomized controlled trial who were treated with NAs for 104 weeks and underwent paired liver biopsies. Histological evaluation was performed at baseline and Week 104. The patients were divided into four groups according to NAFLD status changes. From baseline to Week 104, the overall percentage of CHB patients with concurrent NAFLD increased from 17.1% to 26.2% ( p = 0.044). Among them, 7 of 28 patients (25.0%) with NAFLD at baseline showed NAFLD remission at week 104, while 22 of 136 patients (16.2%) without NAFLD at baseline developed new‐onset NAFLD. In subgroup analyses, the new‐onset and sustained NAFLD groups showed significantly lower rates of biochemical response at week 104 as compared to the sustained non‐NAFLD group (77.3% and 57.1% vs. 93.9%, respectively; all p < 0.05), as well as fibrosis improvement (31.8% and 42.9% vs. 69.3%, respectively; all p < 0.05). NAFLD status changes did not influence the virological response, HBeAg seroconversion, and necroinflammation improvement (all p > 0.05). In HBeAg‐positive CHB patients receiving NAs therapy, new‐onset and sustained NAFLD may counteract the benefits of antiviral therapy, reducing the rate of biochemical response and fibrosis improvement. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1002/jmv.28501 |
| الاتاحة: | http://dx.doi.org/10.1002/jmv.28501 https://onlinelibrary.wiley.com/doi/pdf/10.1002/jmv.28501 https://onlinelibrary.wiley.com/doi/full-xml/10.1002/jmv.28501 |
| Rights: | http://onlinelibrary.wiley.com/termsAndConditions#vor |
| رقم الانضمام: | edsbas.11BCB898 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1002/jmv.28501 |
|---|